NADH-IN-1 |
カタログ番号GC70952 |
NADH-IN-1はNADH云があります:ubiquinone酸化還元酵素と祭り抑制IC50値は27μMである。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1432445-15-2
Sample solution is provided at 25 µL, 10mM.
NADH-IN-1 (1 μM) exhibits a short half-life and fast intrinsic clearance indicating that it is readily metabolised by the liver in vivo; shows no adverse effects on primary rat hepatocytes, and does not inhibit the hERG channel[1].
NADH-IN-1 (10 mg/kg; IV or PO; single dosage) produces no observable toxic effects at 10 mg/kg by IV or PO; exhibits a short half-life and high plasma clearance; exhibits high mouse and human serum protein binding, as well as moderate bioavailability[1].
References:
[1]. Devine R, et al. Design, synthesis, and biological evaluation of aryl piperazines with potential as antidiabetic agents via the stimulation of glucose uptake and inhibition of NADH:ubiquinone oxidoreductase. Eur J Med Chem. 2020;202:112416.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *